Hoai.cancercenter.cc

2012 FEBRUARY
BMT
Protocol
Description
Population
Brain
Protocol
Description
Population
Breast
Protocol
Description
Population
A Phase II Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2- Positive Ductal Carcinoma in Situ resected by Lumpectomy A randomized, phase II , open-label study of lapatinib plus trastuzumab versus Maintance after trastuzumab as continued HER2 suppression therapy after completion of first completion of first or or second line trastuzumab plus chemotherapy in subjects with HER2 positive second line chemo and (Closed to
Enrol ment)
A Phase II, Randomized, Multicenter Study of CDX-011 in Patients with Stage I, II or III (T4 not eligible); must have at least 6 axillary or intramammary Phase II Trial of Continuous Schedule AC + G-CSF vs. Q 2 Week (Closed to
Scehdule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Enrol ment) Weekly for 12 Weeks as Post-Operative Adjuvant Theapy in Node-
Positive or High-Risk Node Negative Breast Cancer Phase 1/2, Open-Label, Randomized Study of the Safety, Efficacy, and Pharmacokinetics of Letrozole Plus PD 0332991 (Oral CDK 4/6 Inhibiotr) and amenable to resection ER+, HER2- per central lab; Letrozole Single Agent for the First-Line Treatment of ER Positive, Her2 Negative Advanced Breast Cancer in Postmenopausal Women A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic A Randomized Phase II Trial of the Value of Early Local Therapy for the Intact carcinoma of the breast; imageable tumor in breast; Primary Tumor on Patients with Metastatic Breast Cancer needle bx preferredOne-time blood collection The CARIS Biorepository Research Protocol Tumor, lymph node, tissue, bone marrow or peripheral blood specimen analyzed by Caris Target Now, IHC, flow cytometry, cytogenetics, FISH, A Registry of Caris Target Now™ Test Results (Biomarker Expression Patterns) and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical (Pending SIV)
Sandoz LA-EP06-Pivotal study in breast cancer patients investigating efficacy and safety of LA- Neoadjuvant or Endocrine
Protocol
Description
Population
Inactivated Shingles Vaccine;
A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Randomized Phase II Study of Everolimus Alone versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Locally Unresectable or neuroendocrine primary Colorectal/GI
Protocol
Description
Population
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic A Phase II Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU / Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic CALGB 80405 Adenocarcinoma of the Colon or Rectum Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and Radiation in Immunocompetent Patients with Anal Carcinoma Phase II Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in advanced or metastatic no prior treatment for Patients with Advanced Hepatocellular Carcinoma (HCC) gross inferior margin of the primary tumor must be at least 21 cm from the anal A Phase II Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage II Colon Cancer only 1 prior systemic therapy fr metastatic disease; 1 prior Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients with Stage IV Esophageal or allowed; no prior taxane or Metastatic Esophageal or GE Junction Cancer carcinoid, low grade or well differentiated neuroendocrine, atypical Phase II Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in unresectable metastatic or moderately differentiated Advanced, Poor Prognosis Carcinoid Patients neuroendocrine carcinomaInactivated Shingles Vaccine; A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic A prospective, randomized, open-label trial comparing OnDose based AUC optimized 5-FU administration versus standard Body Surface Area (BSA) dosing in metastatic colorectal cancer patients (mCRC) treated with A randomized, multicenter, opn-label phase II study of RO5083945 in combinatio with FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with KRAS wold-type or mutant metastatic Gastric
Protocol
Description
Population
Inactivated Shingles Vaccine;
A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Genitourinary
Protocol
Description
Population
A Randomized Double-Blinded Phase II Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients Advanced (T4b, N2, N3 chemotherapy for metastatic with Advanced Transitional Cell Carcinoma CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer setting not al owedInactivated Shingles Vaccine; A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic must have castrate-resistant disease; must not have Randomized Phase II Trial of Docetaxel with or without PSATRICOM Vaccine in Patients with Castrate-Resistant Metastatic Prostate Cancer Head and Neck
Protocol
Description
Popluation
no prior chemo or targeted/targeted therapy for A Phase II Randomized Trial of Chemotherapy With or Without Bevacizumab recurrent or metastatic recurrent or metastatic in Patients with Recurrent or Metastatic Head and Neck Cancer SCCHN; no prior bevacizumabInactivated Shingles Vaccine; A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Hematology
Protocol
Description
Population
Registry for all patients with PNH regardless of treatment or date of diagnosis Registry Randomized Phase II Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalomide (Revlimid) Alone and in (SUSPENDED) Combination with Epoetin Alfa (Procrit) in Subjects with Low or Intermediate- Intermediate Risk -1
A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Tumor, lymph node, tissue, bone marrow or peripheral blood specimen analyzed by Caris Target Now, IHC, flow cytometry, cytogenetics, FISH, A Registry of Caris Target Now™ Test Results (Biomarker Expression Patterns) and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Leukemia
Protocol
Description
Population
any patient starting any line of
treatment within the past 2
Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H For Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia A Genetic Risk-Stratified, Randomized Phase II Study of Four (SUSPENDED) Fludarabine/Antibody Combinations For Patients with Symptomatic,
ECOG C10404 Previously Untreated Chronic Lymphocytic Leukemia
Phase II Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in A Phase II Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND # 101261) or Placebo in Newly (SUSPENDED) Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid
ECOG C10603 Leukemia (AML)
An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with ECOG C10403 Untreated Acute Lymphoblastic Leukemia BMS CA180-330: Simplicity Studying Interventions for Managing Patints with Chronic Myeloid Leukemia in Chronic Phase: The 5-Year Prospective Cohort Study Phase II Study of Combination of Hyper-CVAD and Dasatinib with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia ALL involvement in bone remission induction therapy A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzuman Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia Second line CLLat least 1 prior line of treatment with anthracycline- oranthracenedione-based A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Relapsed or Refractory chemoimmunotherapy or MEDI-551-1019 Bendamustine in Adults with Relapsed or Refrcatory CLL A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Tumor, lymph node, tissue, bone marrow or peripheral blood specimen analyzed by Caris Target Now, IHC, flow cytometry, cytogenetics, FISH, A Registry of Caris Target Now™ Test Results (Biomarker Expression Patterns) and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Lung - Non-Small Cell Lung
Protocol
Description
Population
A Phase II Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - II A A randomized, double-blind, placebo-control ed study to evaluate the long-term safety and efficacy of darbepoetin alfa adminstered at 500ug once q. 3 weeks in anemic subjects with advanced NSCLC receiving multi-cycle A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage II A and Stage II B Non-Squamous Non-Small Cell Lung Cancer After Definitive no prior systemic chemotherapy for advanced Randomized Phase II Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC nodule in ipsilateral lobe since last dose A randomized, open-label, Phase II, 2-arm multi-center trial comparing maintenance therapy with pazopanib or pemetrexed in non-progressing subjects with metastatic stage IVA and stgae IVB non-squamous NSCLC after GSK PAZ113758 induction therapy with carboplatin or cisplatin plus pemetrexed A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin in Subjects wth Stage BMS CA184104 IV/Recurrent Non-Small Cell Lung Cancer (NSCLC) Lung - Small Cell Lung
Protocol
Description
Population
Inactivated Shingles Vaccine;
A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum versus Placebo plus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage BMS CA184156 Disease Small Cell Lung Cancer (ED-SCLC Lymphoma
Protocol
Description
Population
Phase II Randomized Study of R-CHOP versus Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas Phase II Randomized, Open-Label Study of Single Agent Ofatumumab versus Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab- A Phase II Trial of Combination Bortezomib and Rituximab as Front-Line Therapy for Low-Grade Non-Hodgkin's Lymphoma An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without Velcade in Previously Untreated Patients with Non- subclassified as the non- central nervous sytem Pharma C05013 Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed Stage II, II or IV follicular radiotherapy or by Lenalidomide/Rituximab in High Risk Follicular Lymphoma A Randomized Phase 4 Study Comparing 2 Intravenous Temsirolimus (TEMSR) relapsed/refractory Regimens in Subjects with Relapsed, Refractory Mantle Cell Lymphoma prior treatment with at least 1 treatment containing rituximab or other anti CD-20 based therapy combined with anthracycline- or A Phase 2 Randomized Open-label Study of <EDI-551 in Adults with Relapsed relapsed or refractory chemotherapyInactivated Shingles Vaccine; A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Melanoma
Protocol
Description
Population
Inactivated Shingles Vaccine;
A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Multiple Myeloma
Protocol
Description
Population
(CLOSED TO
ENROLLMENT)
Celgene
CONNECT: The multiple myeloma disease registry CC-5013 (Lenalidomide) and Low-Dose Dexamthasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction in Patients with Previously Untreated Multiple Myeloma Without an Intent for Immediate Chemo-naïveInactivated Shingles Vaccine; A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Tumor, lymph node, tissue, bone marrow or peripheral blood specimen analyzed by Caris Target Now, IHC, flow cytometry, cytogenetics, FISH, A Registry of Caris Target Now™ Test Results (Biomarker Expression Patterns) and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Pancreatic Cancer
Protocol
Description
Population
A Randomized Phase II Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Supportive Care
Protocol
Description
Population
A randomized, double-blind, placebo-control ed study to evaluate the long-term safety and efficacy of darbepoetin alfa adminstered at 500ug once q. 3 weeks in anemic subjects with advanced NSCLC receiving multi-cycle NSCLC Supportive care Stage 3b-4, receiving first line A Phase II Randomized, Placebo-Controlled, Clinical Trial to Study the Safety Merck V12_011-and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic

Source: http://hoai.cancercenter.cc/files/2010/05/February-2012.pdf